Acute-phase protein alpha-1-acid glycoprotein mediates neutrophil migration failure in sepsis by a nitric oxide-dependent mechanism.
The reduction of circulating neutrophil migration to infection sites is associated with a poor outcome of severe sepsis. alpha-1-Acid glycoprotein (AGP) was isolated from the sera of severely septic patients by HPLC and acrylamide gel electrophoresis and identified by mass spectrometry. Both the isolated protein and commercial AGP inhibited carrageenin-induced neutrophil migration into the rat peritoneal cavity when administered i.v. at a dose of 4.0 microg per rat (95 pmol per rat). Analysis by intravital microscopy demonstrated that both proteins inhibited the rolling and adhesion of leukocytes in the mesenteric microcirculation. The inhibitory activity was blocked by 50 mg/kg aminoguanidine, s.c., and was not demonstrable in inducible nitric oxide synthase (iNOS) knockout mice. Incubation of AGP with neutrophils from healthy subjects induced the production of NO and inhibited the neutrophil chemotaxis by an iNOS/NO/cyclic guanosine 3,5-monophosphate-dependent pathway. In addition, AGP induced the l-selectin shedding by neutrophils. The administration of AGP to rats with mild cecal ligation puncture sepsis inhibited neutrophil migration and reduced 7-day survival from approximately 80% to 20%. These data demonstrate that AGP, an acute-phase protein, inhibits neutrophil migration by an NO-dependent process and suggest that AGP also participates in human sepsis.
Department of Pharmacology, Faculty of Medicine of Ribeirão Preto, University of São Paulo,14049-900 Ribeirao Preto, São Paulo, Brazil.
F L A C
FL
Mestriner
F
F
Spiller
H J
HJ
Laure
F O
FO
Souto
B M
BM
Tavares-Murta
J C
JC
Rosa
A
A
Basile-Filho
S H
SH
Ferreira
L J
LJ
Greene
F Q
FQ
Cunha
D000209:Acute-Phase Proteins / Q000302:isolation & purification / Q000494:pharmacology / Q000502:physiology*; D000818:Animals; D002351:Carrageenan / Q000494:pharmacology; D002465:Cell Movement / Q000187:drug effects; D002851:Chromatography, High Pressure Liquid; D004195:Disease Models, Animal; D006801:Humans; D036904:Leukocyte Rolling / Q000187:drug effects; D008297:Male; D013058:Mass Spectrometry; D009504:Neutrophils / Q000187:drug effects / Q000276:immunology*; D009569:Nitric Oxide; D009961:Orosomucoid / Q000302:isolation & purification / Q000494:pharmacology / Q000502:physiology*; D051381:Rats; D017208:Rats, Wistar; D018805:Sepsis / Q000097:blood / Q000276:immunology*
D000209:Acute-Phase Proteins; D009961:Orosomucoid; D009569:Nitric Oxide; D002351:Carrageenan